CSL share price lifts on half-year earnings beat

CSL has delivered a messy half-year result but appears to have beaten the market's expectations…

| More on:
a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares are rising after the release of its half-year results
  • The biotherapeutics giant delivered an 'untidy' result according to Goldman Sachs
  • However, it appears to have been ahead of expectations

The CSL Limited (ASX: CSL) share price is edging higher on Tuesday morning.

At the time of writing, the biotherapeutics giant's shares are up 0.5% to $306.36.

Why is the CSL share price rising?

The CSL share price is rising today after the market responded relatively positively to the release of the company's half-year results.

For the six months ended 31 December, CSL reported a 19% increase in revenue to US$7,183.5 million and a 10% lift in net profit after tax before amortisation (NPATA) in constant currency to US$1,957 million.

This was driven partly by a five-month contribution from Vifor Pharma, strong growth in immunoglobulin and albumin sales, and record levels of plasma collections.

This allowed the CSL board to lift its interim dividend by 2.9% to US$1.07 per share.

Looking ahead, management has reaffirmed its guidance for FY 2023 NPATA in the range of approximately US$2.7 billion to US$2.8 billion at constant currency.

How does this compare to expectations?

Analysts at Goldman Sachs have had a quick look at the result and given their verdict.

While the broker described the result as "untidy", it acknowledges that it appears "in-line to slightly ahead".

This appears to explain why the CSL share price is rising this morning. It commented:

Juggling various profit lines, we expect the market to focus on a combination of: 1) statutory NPAT (-8% YoY, but flat at constant currency), both seemingly in-line with consensus; and 2) NPATA (+2% YoY, but +10% at constant currency), which appears +3% ahead. CSL may be running slightly ahead of FY guidance on the NPATA adjustments but this is not clear, and we will await further colour on the call. In any case, FY23 guidance for NPATA of $2.7-2.8bn has been reiterated, which we also presume to mean that the prior NPAT guidance remains in effect.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »